Search research articles
Contact Us
Filters
Showing results (61-70 of 156) with videos related to
Page
of 16
Sort By:
Cancer
|
December 20, 2011
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation
Andrea Ferrario, Alessandro Pulsoni, Barbara Olivero, et al.
Leukemia & Lymphoma
|
June 14, 2011
Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy
Stefano Luminari, Marina Cesaretti, Chiara Tomasello, et al.
British Journal of Haematology
|
December 8, 2011
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
Francesco Merli, Stefano Luminari, Fiorella Ilariucci, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
August 14, 2016
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients
Marcia Torresan Delamain, Maria Gomes da Silva, Eliana Cristina Martins Miranda, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
June 25, 2013
Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure
Patrizia Tosi, Barbara Gamberi, Barbara Castagnari, et al.
Leukemia & Lymphoma
|
September 16, 2011
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial
Fortunato Morabito, Stefan Hohaus, Corrado Mammi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 7, 2011
Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma
Paolo G Gobbi, Francesco Valentino, Emilio Bassi, et al.
Hematological Oncology
|
May 23, 2022
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
Rexhep Durmo, Benedetta Donati, Louis Rebaud, et al.
Leukemia & Lymphoma
|
March 21, 2015
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study
Emilio Iannitto, Stefano Luminari, Claudio Tripodo, et al.
Cancers
|
September 28, 2021
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2)
Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 156) with videos related to
Sort By:
Page
of 16
Cancer
|
December 20, 2011
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation
Andrea Ferrario, Alessandro Pulsoni, Barbara Olivero, et al.
Leukemia & Lymphoma
|
June 14, 2011
Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy
Stefano Luminari, Marina Cesaretti, Chiara Tomasello, et al.
British Journal of Haematology
|
December 8, 2011
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
Francesco Merli, Stefano Luminari, Fiorella Ilariucci, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
August 14, 2016
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients
Marcia Torresan Delamain, Maria Gomes da Silva, Eliana Cristina Martins Miranda, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
June 25, 2013
Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure
Patrizia Tosi, Barbara Gamberi, Barbara Castagnari, et al.
Leukemia & Lymphoma
|
September 16, 2011
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial
Fortunato Morabito, Stefan Hohaus, Corrado Mammi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 7, 2011
Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma
Paolo G Gobbi, Francesco Valentino, Emilio Bassi, et al.
Hematological Oncology
|
May 23, 2022
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
Rexhep Durmo, Benedetta Donati, Louis Rebaud, et al.
Leukemia & Lymphoma
|
March 21, 2015
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study
Emilio Iannitto, Stefano Luminari, Claudio Tripodo, et al.
Cancers
|
September 28, 2021
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2)
Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, et al.
Page
of 16